Trial · NCT07270848
Dronedarone Rhythm Intervention for Early Atrial Fibrillation
NCT07270848, Phase 4, Not yet recruiting, Inha University Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Dronedarone Rhythm Intervention for Early Atrial Fibrillation. Trials, record NCT07270848. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07270848
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Dronedarone Rhythm Intervention for Early Atrial Fibrillation
- NCT number
- NCT07270848
- Status
- Not yet recruiting
- Phases
- Phase 4
- Enrollment
- 1,898 participants, estimated
- Lead sponsor
- Inha University Hospital
- Conditions
- Atrial Fibrillation (AF)
- Interventions
- Dronedarone, flecainide, propafenone
- First posted
- 2025-12-08
- Last updated
- 2025-12-22
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Efficacy : Recurrence of Atrial Fibrillation | From randomization up to 12 months | Percentage of participants who experience a recurrence of atrial fibrillation (AF), atrial flutter, or atrial tachycardia lasting 30 seconds or more, as documented by 12-lead ECG, 24-hour Holter monitoring or wearable Holter monitoring |
| Primary | Safety : Rate of Drug Discontinuation Due to Adverse Events | Up to 12 months | Percentage of participants who permanently discontinue the assigned study drug due to any adverse event (AE) or serious adverse event (SAE). |
| Secondary | Change in Atrial Fibrillation-Specific Quality of Life (AF-QoL) | The change in scores will be compared between enrollment (baseline) and the 12-month time point. | The impact of early rhythm control on quality of life will be assessed using the Atrial Fibrillation Quality of Life (AF-QoL) questionnaire. This questionnaire includes items related to psychological, physical, and sexual activity. The total score is standardized to a scale ranging from 0 to 100, with higher scores indicating a better quality of life. |
| Secondary | Medication Adherence | 6 months and 12 months | The proportion of patients who remain on the assigned study medication will be measured. Adherence will be assessed using the Proportion of Days Covered (PDC) calculation. A PDC of 80% or greater is defined as adherent. |
| Secondary | Comparison of Atrial Fibrillation Treatment Options | Up to 12 months | To assess the rates of: (a) use of Non-vitamin K Antagonist Oral Anticoagulants (NOACs), (b) use of medical therapy (rate control and rhythm control), (c) atrial fibrillation catheter ablation, and (d) direct current cardioversion (DCCV). |
| Secondary | Incidence of Other Arrhythmias on Holter or Wearable Patch ECG | Up to 12 months | To compare the detection rate of other arrhythmias (e.g., Premature Atrial Contractions (PAC), Premature Ventricular Contractions (PVC), Atrioventricular (AV) Block, Supraventricular Tachycardia (SVT), and Ventricular Tachycardia (VT)) documented by Holter or wearable patch ECG monitoring. |
| Secondary | Incidence of Major Adverse Cardiovascular Events (MACE) | Up to 12 months | To measure the incidence of: (a) cardiovascular death, (b) stroke, (c) hospitalization for worsening heart failure, and (d) hospitalization for acute coronary syndrome. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 42774368 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07270848
GET https://conductscience.org/api/trials/v1/NCT07270848/registered